Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations.
about
Evolving models of the immunopathogenesis of T cell-mediated drug allergy: The role of host, pathogens, and drug response.A genome-wide association meta-analysis of self-reported allergy identifies shared and allergy-specific susceptibility lociRecent advances of genetic ancestry testing in biomedical research and direct to consumer testingUpdate on neuropathic pain treatment for trigeminal neuralgia. The pharmacological and surgical options.Predicting HLA alleles from high-resolution SNP data in three Southeast Asian populations.Genotyping for severe drug hypersensitivity.Expectations, validity, and reality in pharmacogenetics.HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in EuropeansOral acetazolamide after Boston keratoprosthesis in Stevens-Johnson syndrome.Safety and tolerability of antiepileptic drug treatment in children with epilepsy.Carbamazepine-Induced Stevens-Johnson Syndrome Sparing the Skin Previously Affected by Herpes Zoster Infection in a Patient with Systemic Lupus Erythematosus: A Reverse Isotopic PhenomenonClinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing.Genomics for disease treatment and prevention.Pharmacogenomics of adverse drug reactions: practical applications and perspectives.Bioinformatics challenges for personalized medicinePharmGKB summary: very important pharmacogene information for human leukocyte antigen B.Genomics and drug response.Association of HLA-B*1502 allele with lamotrigine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese subjects: a meta-analysis.HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in Vietnamese.Development of a bipolar disorder biobank: differential phenotyping for subsequent biomarker analysesComparison of tolerability and adverse symptoms in oxcarbazepine and carbamazepine in the treatment of trigeminal neuralgia and neuralgiform headaches using the Liverpool Adverse Events Profile (AEP).National survey and community advisory board development for a bipolar disorder biobank.Establishing the characteristics of an effective pharmacogenetic test for clozapine-induced agranulocytosis.Transitional polytherapy: tricks of the trade for monotherapy to monotherapy AED conversions.The HLA-A*31:01 allele: influence on carbamazepine treatmentCarbamazepine-induced Life-threatening Stevens-Johnson Syndrome and Agranulocytosis: The Maiden Case.Genetic predisposition of life-threatening antiepileptic-induced skin reactions.Pharmacogenetic considerations in the treatment of psychiatric disorders.Pharmacogenetics of toxic epidermal necrolysis.Why, when, and how should pharmacogenetics be applied in clinical studies?: current and future approaches to study designs.The genetics of antiepileptic drug-induced skin reactions.Global formulary review: how do we integrate pharmacogenomic information?Pharmacological management of seizures and status epilepticus in critically ill patients.HLA and pharmacogenetics of drug hypersensitivity.HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review.The emerging agenda of stratified medicine in neurology.Genetics of immune-mediated adverse drug reactions: a comprehensive and clinical review.Personalized medicine approaches in epilepsy.Role of dermatology in pharmacogenomics: drug-induced skin injury.HLA-B*40:02 and DRB1*04:03 are risk factors for oxcarbazepine-induced maculopapular eruption.
P2860
Q26800980-E6217A44-E1F6-4291-B366-ADDBA1041B88Q28293771-E74B4BC6-5662-4AAE-AF29-5CBC50BC6473Q28752510-CF97F8BA-F243-4D5D-A7E8-91F97DF21C40Q30391958-FE2A79DD-FF47-48A3-95FB-F71886EC3FAAQ30793085-50118683-9A81-41EB-93D6-650B5E254FA1Q33582530-239F9CE7-357B-4077-A3A2-966AAD420CD7Q33926313-E8B6C14A-EEFA-4C61-84E8-3308304E57D8Q34172669-EA89C3F1-9CBE-4887-9A9F-DE4B5630230EQ34252093-0968F4A7-9773-4990-A239-12F0169DFEAAQ34281872-445A2352-FF2E-49D9-B814-A4CCC10FF3ACQ34299895-4DB42CF8-DE8C-41C5-955C-052B1D0DF579Q34345953-C54367AD-F725-4A24-89A0-50A20C865876Q34776933-A5FE918C-4CDB-4C0C-BBBD-2425661B2893Q34987138-E98BEA00-095F-4778-A19F-2A1E4F4A7AC8Q35051893-3E5FEFBC-67AB-4285-B1A1-11366F467A7CQ35168561-07BA7CE2-45BC-4BCF-9BA1-1D379DDC3AECQ35252277-BD83AD5E-16ED-4195-AE83-0613DE7E2C70Q35453569-E66C9512-2C65-41D5-9449-F27C01A2B640Q35555607-9B05AE71-537A-421C-8C3B-C6FDB11267DBQ35772628-884A036B-92C5-4BCD-A495-9086CDCB41F0Q36023697-52BC7D31-61F1-4CCF-B299-EB05F99237ABQ36275964-BC264C39-A994-4C1A-81F9-7B5105951198Q36605131-2296497B-2FD1-4B1F-95CD-B338F7CAAEF3Q37313452-A300FD35-0AA9-463A-815B-231E58B8F2F6Q37626751-F9C278D0-0E03-4CB8-9366-BE032EEB963AQ37630027-530EBA1A-0205-4940-8932-B6517D25C0BCQ37650570-4A7244BF-D26B-4366-934B-E8E4C3E7E4EBQ37681573-8720CABE-72A8-49FF-B897-339F659A3EC3Q37763930-4FD1634F-32A3-44F4-9C13-4D433B78A823Q37826340-201B246D-6C21-4A97-82C9-D5D8382CAE9AQ37859622-F46CA967-EE97-4F96-BC4C-B2C7A48D0C92Q37864479-B304497B-EF8E-4E79-8F43-FDECE3073FB9Q37867301-4862BF26-393F-43D3-AF29-008682DDF09BQ38037649-B9E4826C-105D-43D0-BAA3-7661BC427AD3Q38058271-59E2185B-2CCA-4487-82FE-83D41D1625F5Q38169977-5E772793-2D20-4F6B-9BFD-EFD63B47B5FEQ38207944-06DFD644-57A3-4585-B3ED-5EB6E3B517D0Q38262011-361C88D1-6F0E-4161-A31E-83642D6A5DD4Q38396234-CFA968D7-987E-4C8B-8D3B-7E3B10432713Q38410413-EADADB1F-811E-4965-BAC5-A948D6ACCFF6
P2860
Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations.
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Carbamazepine, HLA-B*1502 and ...... lysis: US FDA recommendations.
@ast
Carbamazepine, HLA-B*1502 and ...... lysis: US FDA recommendations.
@en
Carbamazepine, HLA-B*1502 and ...... lysis: US FDA recommendations.
@nl
type
label
Carbamazepine, HLA-B*1502 and ...... lysis: US FDA recommendations.
@ast
Carbamazepine, HLA-B*1502 and ...... lysis: US FDA recommendations.
@en
Carbamazepine, HLA-B*1502 and ...... lysis: US FDA recommendations.
@nl
prefLabel
Carbamazepine, HLA-B*1502 and ...... lysis: US FDA recommendations.
@ast
Carbamazepine, HLA-B*1502 and ...... lysis: US FDA recommendations.
@en
Carbamazepine, HLA-B*1502 and ...... lysis: US FDA recommendations.
@nl
P2860
P1433
P1476
Carbamazepine, HLA-B*1502 and ...... olysis: US FDA recommendations
@en
P2093
Howard L McLeod
P2860
P304
P356
10.2217/14622416.9.10.1543
P577
2008-10-01T00:00:00Z